Navigation Links
PAREXEL Reports Third Quarter Fiscal Year 2011 Financial Results
Date:5/2/2011

BOSTON, May 2, 2011 /PRNewswire/ -- PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the third quarter ended March 31, 2011.

For the three months ended March 31, 2011, PAREXEL’s consolidated service revenue increased by 3.5% to $301.4 million, compared with $291.2 million in the prior year period.  Excluding the positive impact from foreign exchange movements of $3.3 million, revenue increased 2.4%, to $298.1 million.  As reported under Generally Accepted Accounting Principles (GAAP), the Company generated operating income of $21.9 million, or 7.3% of consolidated service revenue, in the third quarter of Fiscal Year 2011, versus GAAP operating income of $25.8 million, or 8.9% of consolidated service revenue, in the comparable quarter of the prior year.   On this basis, GAAP operating income declined 15.3% year-over-year.  The financial results of the March quarter in the current and prior periods each included special items, as detailed in the financial charts within this press release.  Excluding these special items in the current period, adjusted operating income totaled $22.4 million, or 7.4% of consolidated service revenue.  Excluding the special items referenced above in the prior year period, adjusted operating income totaled $29.9 million, or 10.3% of consolidated service revenue.  On this adjusted basis, operating income in the current quarter declined 25.1% year-over-year.  GAAP net income for the current quarter totaled $15.7 million, or $0.26 per diluted share, compared with GAAP net income of $12.8 million, or $0.22 per diluted share, for the quarter ended March 31, 2010.  On a GAAP basis, net income in the current quarter increased by 23.1%, and earnings per diluted share increased by 18.2%.  Adjusted net income in the current period (which excludes the special items referenced above) was $16.1 million, or $0.27 per diluted share.  Adjusted net income in the prior year quarter (which excludes the special items referenced above) was $16.8 million, or $0.28 per diluted share. Using adjusted numbers, net income in the current quarter declined by 4.5%, and earnings per diluted share declined by 3.6%.

The financial results in the third quarter were adversely impacted by a revenue shortfall in the Early Phase operating unit of Clinical Research Services, slower than expected revenue conversion from backlog related to strategic partnerships, and client delays on some large projects.  In addition, the Company continues to have a disproportionate number of projects in the lower revenue generating start-up stage.

The Company’s current quarter tax benefit of approximately $900,000 resulted from a reduction in the estimated full-year tax rate due to a more favorable geographic mix of pre-tax profitability.  At the same time, the Company experienced higher-than-anticipated foreign exchange losses on the Other Expense line, due in part to cash flow variability caused by implementation of the Company’s new billing system and the resulting delay in intercompany settlements.  

The quality of the Company’s net receivables continued to improve with sequential increases in both billed receivables and deferred revenue coupled with a decrease in unbilled receivables.  However, Days Sales Outstanding (DSO) increased to 72 days at March 31, 2011 as a result of lower gross revenue.  On a related note, operating cash flow was $27.2 million in the quarter.

On a segment basis, consolidated service revenue for the third quarter of Fiscal Year 2011 was $227.0 million in Clinical Research Services (CRS), $34.1 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $40.3 million in Perceptive Informatics, Inc.

For the nine months ended March 31, 2011, consolidated service revenue was $901.6 million versus $835.7 million in the prior year period, an increase of 7.9%.  GAAP operating income for the current nine-month period was $80.1 million, or 8.9% of consolidated service revenue, compared with GAAP operating income of $63.0 million, or 7.5% of consolidated service revenue in the prior year period.  GAAP net income for the nine months ended March 31, 2011 was $50.4 million, or $0.84 per diluted share, compared with GAAP net income of $28.7 million, or $0.49 per diluted share, in the prior year period.  Excluding the impact of certain special items as detailed in the attached financial charts in both nine month periods, adjusted operating income was $79.6 million, or 8.8% of consolidated service revenue, for the nine months ended on March 31, 2011, compared with $75.3 million or 9.0% of consolidated service revenue for the nine months ended on March 31, 2010.  On an adjusted basis, net income for the nine months ended March 31, 2011 was $50.8 million, or $0.85 per diluted share, compared with $44.4 million, or $0.76 per diluted share, in the comparable prior year nine month period.

Backlog at the end of March was approximately $3.19 billion, an increase of approximately 34% year-over-year.  Backlog included gross new business wins in the quarter of $566.5 million, cancellations of $132.4 million (4.4% of beginning backlog), and a positive impact from foreign exchange rates of $33.6 million. The net book-to-bill ratio was 1.44 in the quarter.

The Company also announced its plans to commence a restructuring program beginning in the fourth quarter of Fiscal Year 2011, primarily focused on Early Phase capacity reductions.  The amount of the restructuring is estimated to total approximately $15.0 million (equating to approximately $0.18 per diluted share), of which approximately $4.0 million is expected to be recorded in the fourth quarter, negatively impacting earnings per diluted share by approximately $0.06.  The remaining $0.12 is expected to be recorded in the second half of calendar year 2011.  The restructuring is expected to generate cost savings in the range of $0.15 to $0.20 per diluted share during FY 2012.  These amounts have been factored into the Company’s forward-looking guidance.

Mr. Josef H. von Rickenbach, PAREXEL’s Chairman and Chief Executive Officer, stated “The Early Phase market is clearly in transition.  As industry conditions shift, our business must also adapt.  To continue to serve our clients well in the future, it is essential that we become more agile in our Early Phase business.  I believe that this restructuring will allow us to deploy our assets more productively.  We are also strategically positioning the business to take advantage of new market opportunities.”

Mr. von Rickenbach noted, “During the third quarter, a shortfall in Early Phase revenue and slower than expected revenue conversion from backlog in the rest of CRS negatively impacted the quarter’s results.  Delays with a few key programs have pushed revenue out to future quarters, while, at the same time, we have a significant number of large projects in backlog that continue to be in the lower revenue generating start-up stages.”

He continued, “With regard to new business, PAREXEL again achieved a very strong book-to-bill ratio, coming in at 1.44 this quarter.  I am very pleased with our robust level of new business wins and the success that we continue to have in the marketplace.  Also, the strength of our established Asia Pacific infrastructure continues to be very well received by clients.”

In discussing the future outlook for the Company, Mr. von Rickenbach stated, “While revenue continues to convert out of backlog more slowly than had been expected, cancellations were within normal levels this quarter, and our opportunity pipeline and backlog remain very solid.  Given our new business performance and our expected growth, we are accelerating recruitment of additional direct labor staff in our Clinical Research Services business to ensure that we meet the future project needs of our clients.  This ramp-up in hiring is taking place ahead of significant levels of revenue being generated from these projects, which will put pressure on operating margins in the near-term.  I believe that our future is promising.  Based on our current backlog and outlook, we anticipate mid-teens revenue growth in the second half of Fiscal Year 2012.  This is an exciting time for our industry, and we believe that we are well-positioned to continue to increase our share of the market.”

The Company issued forward-looking guidance for the fourth quarter of Fiscal Year 2011 (ending June 30, 2011), for Fiscal Year 2011 and for Calendar Year 2011 using recent exchange rates.   For the fourth quarter, the Company anticipates reporting consolidated service revenue in the range of $300.0 to $310.0 million, GAAP diluted earnings per share in the range of $0.00 to $0.04 and adjusted diluted earnings per share (which excludes the aforementioned restructuring charge) of $0.05 to $0.09. For Fiscal Year 2011, consolidated service revenue is expected to be in the range of $1.202 to $1.212 billion (previously issued revenue guidance was $1.220 to $1.240 billion).  GAAP earnings per diluted share for Fiscal Year 2011 are projected to be in the range of $0.84 and $0.88 (previously issued GAAP earnings per diluted share guidance was $1.17 to $1.23), and adjusted earnings per diluted share (which excludes the restructuring charge and the special items referenced above) are projected to be in the range of $0.90 and $0.94.  For Calendar Year 2011, consolidated service revenue is expected to be in the range of $1.245 to $1.275 billion (previously issued revenue guidance was $1.260 to $1.295 billion), GAAP earnings per diluted share are expected to be in the range of $0.57 to $0.70 (previously issued guidance was $1.21 to $1.31), and adjusted earnings per diluted share (excluding the restructuring charge and the special items referenced above) are projected to be in the range of $0.76 and $0.89.

Certain trended financial information may be found in the Investor Relations section of the Company’s website under the “Additional Financials” section.  

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures.  The Company believes that presenting the non-GAAP financial measures contained in this press release assists investors and others in gaining a better understanding of its core operating results and future prospects, especially when comparing such results to previous periods or forecasted guidance, because such measures exclude items that are outside of the Company’s normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.  Management uses non-GAAP financial measures, in addition to the measures prepared in accordance with GAAP, as the basis for measuring the Company’s core operating performance and comparing such performance to that of prior periods and to the performance of its competitors for the same reasons stated above.  Such measures are also used by management in its financial and operating decision-making.  Non-GAAP financial measures are not meant to be considered superior to or a substitute for the Company’s results of operations prepared in accordance with GAAP.  

A conference call to discuss PAREXEL’s third quarter earnings, business, and financial outlook will begin at 10:00 a.m. ET on Tuesday, May 3, 2011 and will be broadcast live over the internet via webcast.  The webcast may be accessed in the “Upcoming Events” portion of the main page of the Investor Relations section of the Company’s website at www.parexel.com.  Users should follow the instructions provided to assure that the necessary audio applications are downloaded and installed.  A replay of this webcast will be archived on the website approximately two hours after the call and will continue to be accessible for approximately one year following the live event.  To participate via telephone, dial +1 (408) 940-3886 and ask to join the PAREXEL quarterly conference call.

About PAREXEL International PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,350 employees. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $15 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2010 as filed with the SEC on February 9, 2011, which “Risk Factors” discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.PAREXEL International Corporation Consolidated Condensed Statement of OperationsUnauditedThree Months EndedThree Months Ended(in thousands, except per share data)March 31, 2011March 31, 2010As ReportedAdjustmentsNon-GAAPAs ReportedAdjustmentsNon-GAAPService revenue$
301,396$   301,396$
291,244$  291,244Reimbursement revenue51,56551,56553,16253,162  Total revenue352,961-352,961344,406344,406Costs and expenses:Direct costs192,507(368)

(b)

192,139181,810

(a)181,810Reimbursable out-of-pocket expenses51,56551,56553,16253,162Selling, general and administrative 70,798(7)

(b)

70,79164,304

(a)64,304Depreciation13,58213,58212,43964

(c)

12,503Amortization2,5002,5002,7482,748 Other benefit ----Restructuring charge144(144)

(c)

-4,119(4,119)

(c)

-  Total costs and expenses331,096(519)330,577318,582(4,055)314,527Income from operations21,86551922,38425,8244,05529,879Other expense(7,003)(7,003)(6,350)430

(d)

(5,920)Income before income taxes14,86251915,38119,4744,48523,959Provision for income tax expense (benefits)(872)181

(e)

(691)6,691439

(e)

7,130Effective tax rate-5.9%-4.5%34.4%29.8%Net income$
5,734$
338$
,072$
2,783$
4,046$
,829Earnings per common share:  Basic$
.27$
.27$
.22$
.29  Diluted$
.26$
.27$
.22$
.28Shares used in computing earnings per common share:  Basic58,67358,67358,13558,135  Diluted59,80859,80859,18459,184(a) Prior year numbers have been reclassified to conform with the current year presentation.(b) Severance associated with FY11 restructuring activities.(c) Restructuring charges pursuant to plans announced or implemented in Q3 FY10 include $0.5 million of facility-related costs and $3.6 million in severance costs.  The Q3 FY11 charge is related primarily to additional severance costs on the FY10 restructuring plan.(d) Asset impairment charge.(e) Taxes associated with items (b) - (d).Balance Sheet InformationPreliminaryMarch 31,December 31,June 30,March 31,2011201020102010Billed accounts receivable, net

$
355,733$
311,377$
229,932$   250,642Unbilled accounts receivable, net

279,832285,977248,994237,001Deferred revenue

(321,007)(285,576)(261,080)(279,874)Net receivables

$
314,558$
311,778$
217,846$   207,769Cash and marketable securities

$
9,424$
87,552$
7,413$   117,809Working capital

$
251,803$
217,170$
58,624$   181,930Total assets

$ 1,443,834$
,356,032$
,220,710$1,227,887Short-term borrowings

$
,787$
,019$
32,082$
32,082Long-term debt

$
77,583$
72,230$
83,707$   192,626Stockholders' equity

$
558,763$
516,714$
439,555$   444,283PAREXEL International Corporation Consolidated Condensed Statement of OperationsUnauditedNine Months EndedNine Months Ended(in thousands, except per share data)March 31, 2011March 31, 2010As ReportedAdjustmentsNon-GAAPAs ReportedAdjustmentsNon-GAAPService revenue$
901,575$  901,575$
835,738$  835,738Reimbursement revenue157,693157,693154,186154,186  Total revenue1,059,268-1,059,268989,924989,924Costs and expenses:Direct costs575,964(368)

(b)

575,596534,074

(a)534,074Reimbursable out-of-pocket expenses157,693157,693154,186154,186Selling, general and administrative 198,514(7)

(b)

198,507181,957

(a)181,957Depreciation40,43840,43837,159(450)

(c)

36,709Amortization7,4087,4087,7317,731 Other benefit -(1,144)1,144

(d)

-Restructuring (benefit) charge(818)818

(c)

-12,950(12,950)

(c)

-  Total costs and expenses979,199443979,642926,913(12,256)914,657Income from operations80,069(443)79,62663,01112,25675,267Other expense(22,791)1,166

(e)

(21,625)(17,074)6,572

(e)

(10,502)Income before income taxes57,27872358,00145,93718,82864,765Provision for income taxes6,921270

(f)

7,19117,2633,106

(f)

20,369Effective tax rate12.1%12.4%37.6%31.5%Net income$
50,357$
453$
50,810$
28,674$
5,722$
44,396Earnings per common share:  Basic$
.86$
.87$
.49$
.77  Diluted$
.84$
.85$
.49$
.76Shares used in computing earnings per common share:  Basic58,54558,54557,96057,960  Diluted59,71759,71758,46358,463(a) Prior year numbers have been reclassified to conform with the current year presentation.(b) Severance associated with FY11 restructuring activities.(c) Restructuring charges pursuant to plans announced or implemented in Q2 and Q3 FY10 include $0.4 million of accelerated depreciation on abandoned facilities, $5.8 million of facility-related costs and $7.2 million in severance costs.  The FY11 charge is related primarily to additional severance costs on the FY10 restructuring plan.(d) Release of $1.1 million in certain reserves related to the $15 million wind-down costs and bad debt expense established in Q2 FY09 for a client contract default.(e) Impairment charge on an asset (FY11) and investment (FY10).(f) Tax associated with items (b) - (e).PAREXEL International CorporationSegment InformationUnauditedThree Months EndedThree Months Ended(in thousands)

March 31, 2011March 31, 2010 (a)As ReportedAdjustmentsNon-GAAPAs ReportedClinical Research Services (CRS)Service revenue

$
227,006$  227,006$
221,456% of total service revenue

75.3%75.3%76.0%Gross profit

$
77,955201

(b)

$
78,156$
79,058Gross margin % of service revenue

34.3%34.4%35.7%PAREXEL Consulting & Medical Communications  Services (PCMS)Service revenue

$
34,136$
34,136$
31,518% of total service revenue

11.3%11.3%10.8%Gross profit

$
3,66555

(b)

$
3,720$
2,682Gross margin % of service revenue

40.0%40.2%40.2%Perceptive Informatics, Inc. (PII)Service revenue

$
40,254$
40,254$
38,270% of total service revenue

13.4%13.4%13.2%Gross profit

$
7,269112

(b)

$
7,381$
7,694Gross margin % of service revenue

42.9%43.2%46.2%Total service revenue$
301,396$  301,396$
291,244Total gross profit$
8,889368$  109,257$
9,434Gross margin % of service revenue36.1%36.3%37.6%Revenue by GeographyThe Americas

$
,996$  106,996$
4,972Europe, Middle East & Africa

146,008146,008141,810Asia/Pacific

48,39248,39234,462Total service revenue

$
301,396$  301,396$
291,244Quarterly Supplemental Financial DataTotal revenue

$
352,961$  352,961$
344,406Investigator fees

38,55738,55750,988Gross revenue

$
391,518$  391,518$
395,394Days sales outstanding

7247Capital expenditures

11,06318,624(a) Prior year numbers have been reclassified to conform with the current year presentation.(b) Severance associated with FY11 restructuring activities.PAREXEL International CorporationSegment InformationUnauditedNine Months EndedNine Months Ended(in thousands)

March 31, 2011March 31, 2010 (a)As ReportedAdjustmentsNon-GAAPAs ReportedClinical Research Services (CRS)Service revenue

$
90,009$  690,009$
45,350% of total service revenue

76.5%76.5%77.2%Gross profit

$
238,129201

(b)

$  238,330$
228,098Gross margin % of service revenue

34.5%34.5%35.3%PAREXEL Consulting & Medical Communications  Services (PCMS)Service revenue

$
94,484$
94,484$
90,070% of total service revenue

10.5%10.5%10.8%Gross profit

$
37,64255

(b)

$
37,697$
33,445Gross margin % of service revenue

39.8%39.9%37.1%Perceptive Informatics, Inc. (PII)Service revenue

$
7,082$  117,082$
,318% of total service revenue

13.0%13.0%12.0%Gross profit

$
49,840112

(b)

$
49,952$
40,121Gross margin % of service revenue

42.6%42.7%40.0%Total service revenue$
901,575$  901,575$
835,738Total gross profit$
325,611368$  325,979$
301,664Gross margin % of service revenue36.1%36.2%36.1%Revenue by GeographyThe Americas

$
367,081$  367,081$
325,486Europe, Middle East & Africa

407,738407,738413,809Asia/Pacific

126,756126,75696,443Total service revenue

$
901,575$  901,575$
835,738(a) Prior year numbers have been reclassified to conform with the current year presentation.(b) Severance associated with FY11 restructuring activities.CONTACTS:

James Winschel, Senior Vice President and Chief Financial OfficerJill Baker, Corporate Vice President, Investor Relations+1-781-434-4118
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Key Presentations Announced for Landmark Future of Biosimilars Event Co-Sponsored by DIA and FDLI, Co-Chaired by Merck and PAREXEL
2. PAREXEL Expert Serves as Lead Author and Editor of Definitive Resource on Quality by Design (QbD), Aimed at Maximizing Product Quality and Speeding Treatments to Market
3. PAREXEL Announces Date of Third Quarter Fiscal Year 2011 Earnings Release and Conference Call
4. PAREXEL Experts To Address Best-Practice Strategic Partnership Models To Increase Operating Efficiency, Development Effectiveness at Partnerships in Clinical Trials
5. PAREXEL Experts to Present Advanced Approaches to Accelerate Development, Maximize Product Value at DIA EuroMeeting
6. PAREXEL International to Present at Raymond James Investors Conference
7. PAREXEL International to Present at J.P. Morgan Healthcare Conference
8. PAREXEL Opens Clinical Logistics Facilities in Singapore and Russia
9. PAREXEL Wins Clinical Research Team of the Year Scrip Award
10. PAREXEL International to Participate in the Lazard Capital Markets Healthcare Conference in New York and the Jefferies Healthcare Summit in Boston
11. PAREXEL Expert to Lead Track on Global Clinical Outsourcing at Partnerships in Clinical Trials Europe Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):